重症监护病房中褪黑素的使用:系统综述与Meta分析
该系统综述与Meta分析纳入32项随机对照试验(n=3895例ICU成人),比较褪黑素与不用褪黑素。结果显示,褪黑素可能减少谵妄(RR 0.72;95%CI 0.58-0.89;低确定性),可能轻微缩短ICU住院时间(MD -0.57天;95%CI -0.95至-0.18天;低确定性),并可能改善报告的睡眠质量(SMD 0.54;95%CI 0.01-1.07;低确定性)。褪黑素可能轻微减少不良事件频率(低确定性)。关于睡眠觉醒频率、焦虑水平、躁动和创伤后应激障碍发生率(均极低确定性)以及ICU死亡率和ICU后功能状态(均低确定性),证据不确定。作者认为褪黑素可能改善主观睡眠并减少谵妄而不增加不良事件,但证据确定性受偏倚风险和不一致性影响;未来随机对照试验应关注最佳剂量、给药时机、改善睡眠结局测量和目标人群。
要点
- 在ICU成人中,褪黑素可能减少谵妄:RR 0.72(95%CI 0.58-0.89),证据确定性低。
- 褪黑素可能轻微缩短ICU住院时间:MD -0.57天(95%CI -0.95至-0.18天),证据确定性低。
- 褪黑素可能改善报告的睡眠质量:SMD 0.54(95%CI 0.01-1.07),证据确定性低。
- 褪黑素可能轻微减少不良事件频率(低确定性);对ICU死亡率、睡眠觉醒频率、焦虑、躁动、创伤后应激障碍及ICU后功能状态证据不确定。
- 作者认为褪黑素可能改善主观睡眠并减少谵妄而不增加不良事件;未来随机对照试验应关注最佳剂量、给药时机、睡眠结局测量和目标人群。
适用人群与场景
- 成人(≥18岁)入住ICU的患者,纳入比较褪黑素与不用褪黑素的随机对照试验。
研究设计与关键结果
- 研究类型:系统综述与Meta分析,纳入32项随机对照试验,共3895例ICU成人患者。
- 干预与对照:褪黑素 vs 不用褪黑素。
- 主要终点:谵妄——褪黑素组较对照组减少,RR 0.72(95%CI 0.58-0.89),证据确定性低。
- 关键次要终点:ICU住院时间——褪黑素组较对照组缩短,MD -0.57天(95%CI -0.95至-0.18天),证据确定性低;报告的睡眠质量——褪黑素组较对照组改善,SMD 0.54(95%CI 0.01-1.07),证据确定性低。
- 不良事件:褪黑素可能轻微减少不良事件频率(低确定性)。
- 其他终点:睡眠觉醒频率、焦虑水平、躁动和创伤后应激障碍发生率证据不确定性均为极低;ICU死亡率和ICU后功能状态证据确定性均为低。
证据类型、等级与局限
- 证据类型:系统综述与Meta分析,纳入32项随机对照试验(n=3895),采用随机效应模型,使用GRADE方法评估证据确定性。
- 证据确定性:谵妄、ICU住院时间、睡眠质量、不良事件均为低确定性;睡眠觉醒频率、焦虑水平、躁动、创伤后应激障碍发生率均为极低确定性;ICU死亡率和ICU后功能状态均为低确定性。
- 局限:证据确定性受偏倚风险和不一致性影响。
对床旁实践的改变
- 作者认为褪黑素可能改善ICU患者的主观睡眠并减少谵妄,且不增加不良事件;未来随机对照试验应关注最佳剂量、给药时机、改善睡眠结局测量和目标人群。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Melatonin has wide-ranging effects on the body, including the regulation of circadian rhythm, and potentiation of cellular immune and antioxidant activities. In critically ill patients, endogenous melatonin has been shown to be markedly deranged and reduced. Therefore, the purpose of this systematic review and meta-analysis was to determine if exogenous supplementation of melatonin improves patient-centered outcomes.
DATA SOURCES: We searched five electronic databases.
STUDY SELECTION: Randomized clinical trials (RCTs) that compared melatonin to no melatonin in adults admitted to the ICU were identified.
DATA EXTRACTION: We aggregated data as relative risks, mean differences (MDs), and standard mean differences (SMDs) using a random-effects model. Supporting evidence for each effect was evaluated for certainty using the Grading Recommendations, Assessment, Development, and Evaluations approach.
DATA SYNTHESIS: In total, 32 RCTs ( n = 3895 patients) were included. We found that melatonin may reduce delirium (relative risk [RR] 0.72; 95% CI, 0.58-0.89; low certainty), may slightly reduce ICU length of stay (MD -0.57 d; 95% CI, -0.95 to -0.18 d; low certainty), and may improve reported sleep quality (SMD 0.54; 95% CI, 0.01-1.07; low certainty). Melatonin may result in a slight reduction in the frequency of adverse events (low certainty). Evidence was uncertain with regards to the frequency of sleep awakenings, anxiety level, agitation, and post-traumatic stress disorder incidence (all very low certainty), as well as to ICU mortality and post-ICU functional status (both low certainty).
CONCLUSIONS: Our findings suggest that melatonin administration in the critically ill may improve perceived sleep and reduce delirium, without increasing adverse effects. Certainty of evidence was negatively affected by the risk of bias and inconsistency. Future RCTs should focus on identifying optimal dosing, administration timing, improving measurements of sleep outcomes, and target populations.
参考来源
- Tang BHY, Manalo J, Chowdhury SR, et al. Melatonin Use in the ICU: A Systematic Review and Meta-Analysis. Crit Care Med. 2025. PMID: 40662882. doi:10.1097/CCM.0000000000006767
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。